EZH2 and malignant peripheral nerve sheath tumor: Loss-of-function mutations in PRC2 components (e.g., EED, SUZ12) have been implicated in MPNST development, and therapies targeting EZH2, an enzyme within PRC2, have shown preclinical promise [20].